Socio-demographic profile of metabolic syndrome in patients treated with antipsychotic drugs: A tertiary hospital based study in eastern region of Nepal.
ABSTRACT: Background: Currently, second-generation antipsychotic drugs are widely used in Nepal to treat mental illness. The risk of developing metabolic syndrome after treatment with antipsychotic drugs has not been fully estimated. The purpose of this study was to evaluate the socio-demographi...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
c2020.
|
| Subjects: | |
| Online Access: | Visit NHRC Library |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | ABSTRACT: Background: Currently, second-generation antipsychotic drugs are widely used in Nepal to treat mental illness. The risk of developing metabolic syndrome after treatment with antipsychotic drugs has not been fully estimated. The purpose of this study was to evaluate the socio-demographic characteristics and associated factors of metabolic syndrome in patients being treated with antipsychotic drugs. Methods: A cross-sectional study was conducted among 286 patients who were receiving antipsychotic drugs for at least three months at the psychiatric outpatient department of the BPKIHS. Data were collected using a semi-structured proforma, and all measurements were recorded. Fasting blood samples were collected for biochemical parameter estimation. Metabolic syndrome was assessed based on the Modified Asian NCEP-ATP III criteria. Results: The overall prevalence of metabolic syndrome was 52.4% (95% CI, 47.2% - 57.6%). It was more common among females as compared to males (54.1% vs. 50.7%). The most common metabolic abnormalities were abnormal waist circumference (78.0%) followed by low HDL cholesterol, hypertriglyceridemia, increased fasting glucose, and elevated blood pressure. Abnormal waist circumference and reduced HDL cholesterol were significantly higher among females. Only BMI (P < 0.001) of the patients was a significant predictor of the metabolic syndrome. Duration of disease, duration of treatment and all metabolic subcomponents were significantly different in the presence and absence of metabolic syndrome. Conclusion: More than half of patients receiving antipsychotic medication have metabolic syndrome. It is more common among females, and females are more affected by increased waist circumference and decreased HDL cholesterol. BMI and disease relapse are significant risk factors associated with the metabolic syndrome. Keys words: Antipsychotic drugs, Metabolic syndrome, Olanzapine |
|---|---|
| Item Description: | Research Report. |
| Physical Description: | iv,55p. |